Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 14Prostatic Neoplasms 4Neoplasms 3Carcinoma, Intraductal, Noninfiltrating 3Precancerous Conditions 2Peripheral Nervous System Diseases 2Lung Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Cardiovascular Diseases 2Breast Carcinoma In Situ 2Weight Loss 1Urologic Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Smoldering Multiple Myeloma 1Sarcoma 1Psoriasis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polyps 1Polycystic Ovary Syndrome 1Pain 1Ovarian Neoplasms 1Osteoarthritis 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1

Interventions

Escitalopram 3Psilocybin 2Interpersonal Psychotherapy 2Infliximab 2abacavir 1Vortioxetine 1Venlafaxine Hydrochloride 1Transcranial Magnetic Stimulation 1Sugars 1Saline Solution 1Mirtazapine 1Magnetic Resonance Spectroscopy 1Ketamine 1Fatty Acids, Omega-3 1Diagnostic Imaging 1Desvenlafaxine Succinate 1Cognitive Behavioral Therapy 1Citalopram 1Bupropion 1Antidepressive Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Depressive Disorder, Major × Fatty Acids, Omega-3 × Clear all
NCT01803711 2017-12-27

Omega 3 FA Supplements as Augmentation in the Treatment of Depression

UConn Health

Phase 2/3 Terminated
6 enrolled 4 charts

Cardiovascular Diseases, Depression, Depressive Disorder, Major, Diabetes Mellitus, Hypertension, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡